berezko / iStockphoto.com
The inter partes review (IPR) process has had a huge impact on biosimilar litigation, but it isn’t truly fulfilling its goal of being an alternative to district court litigation.
You need a subscription to continue reading this content.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
AIPPI 2018, Eli Lilly, IPR, inter partes review, biosimilar, UCB, Manisha Desai, Mark Stewart